Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
Coronary Artery Disease

Coronary Artery Disease

Innovation continues to advance technologies in coronary artery disease (CAD)—beyond simply managing CAD to repairing, restoring and healing vasculature. Abbott technologies enable physicians to approach each patient with sophisticated insights from imaging and physiology assessments to identify the presence or absence of ischemia, and interventional therapies with proven safety that have become the industry’s gold standard.

As a global leader in cardiology, Abbott is dedicated to supporting healthcare professionals no matter how simple or complex their CAD cases may be. We’re all striving toward the same goal: offering optimal therapies, ensuring patient safety and improving their health.

Imaging

Optical coherence tomography (OCT) provides the intravascular imaging guidance that physicians increasingly turn to during PCI to guide decision-making. Angiography’s two-dimensional (2D) imaging, while beneficial, has inherent limitations. But with three-dimensional (3-D) OCT imaging it’s possible to quantify plaque morphology, as well as calcium location and severity.1 3-D OCT imaging allows the quantification of plaque morphology, plus assessment of coronary calcium location and its severity.2 OCT offers angiographic co-registration to guide precise stent placement and review post-deployment results to optimize stent expansion.2 Discover the benefits of Abbott’s OCT imaging today.

Imaging

Physiology

Physiological measurements such as fractional flow reserve (FFR) and resting full-cycle ratio (RFR) can be used to evaluate the functional significance of coronary stenosis.3,4 Beyond the visibility of angiography, index of microcirculatory resistance (IMR) and coronary flow reserve (CFR) can be used to diagnose coronary microvascular dysfunction.5,6 A comprehensive physiology assessment can improve PCI outcomes and patients quality of life.5,7-8

Imaging

DAPT

The post-PCI decision about dual antiplatelet therapy (DAPT) duration must be individualized for each patient. However, Abbott’s XIENCE™ Stents provide the only 28-day DAPT labeling option for patients at high bleeding risk.9 With the increasing numbers of complex cases, safety data on Abbott stents—for both short-term and long-term DAPT duration—can offer assurance to healthcare professionals focused on patient safety.10

DAPT

References

  1. Ultreon™ 1.0 Software Instructions for Use (IFU). Refer to IFU for additional information.
  2. Reyes, M. The next innovation in PCI is not a stent. The value of OCT. CathLab Digest. Oct 6, 2019. Volume 27, Issue 10.
  3. PressureWire™ X GuideWire Instructions for Use (IFU). Refer to IFU for additional information.
  4. Svanerud J, et al. Validation of a novel non-hyperaemic index of coronary artery stenosis severity: the Resting Full-cycle Ratio (VALIDATE RFR) study. EuroIntervention. 2018;14:806-814.
  5. Ford T, et al. CorMicA Trial. 2018; 72(23): 2841-55 with online appendix.
  6. Kunadian V, et al. EHJ & Eurointervention 2020: ehaa503. DOI:10.1093/eurheartj/ehaa503.
  7. Tonino PA, et al. Angiographics versus functional severity of coronary artery stenoses in the FAME study: Fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 2010; 55:2816-21.
  8. De Bruyne B, et al. FFR Guided PCI versus Medical Therapy in Stable Coronary Disease, NEJM. 2012; 367 (11): 991-1001
  9. XIENCE Skypoint Instructions for Use (IFU). Refer to IFU for additional information.
  10. Zanchin C, et al. J Am Coll Cardiol Intv. 2019;12:1665-1675.

MAT-2202837 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO